Cytosurge is a biotechnology company that provides the world’s only technology that allows scientists to physically access, perturb, and profile the same living cell over time, enabling insights that snapshot methods cannot capture > FluidFM combines microfluidics and force microscopy to enable gentle interactions with cells; based on this unique technology, we empower scientists to read, write, and analyze life as it unfolds. Experience the revolution of Same-Cell Biology with FluidFM OMNIUM. The single-cell biopsy solution on the FluidFM OMNIUM platform provides a unique workflow for extraction of a part of the cytoplasm from individual living cells while preserving their viability. These cytoplasmic biopsies can be used for subsequent highly sensitive, low-input RNA-seq analysis to characterize single-cells multiple times throughout their lifetime. This enables temporal profiling to track how baseline states and treatments causally drive future behavior, delivering data that reveals mechanisms rather than just correlations. CellEDIT service: Vector-free, controlled genome engineering. Empowered by FluidFM, CellEDIT delivers precise doses without vectors, multiplex edits even in hard-to-transfect cells—without viral toxicity or electroporation. We provide unprecedented control to generate clean, reproducible, and physiologically relevant models. Finally obtain the edits you need, reliably. You name the edit, we edit it. BOOTH #617.
Cytiva
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more. | Diagnostic assays like the ones you’re developing are in demand. Set yourself up for success by choosing a supplier that delivers quality products for your entire workflow and offers specialized services and capabilities needed to commercialize your assays. Using a single supplier for multiple components, from membranes to magnetic beads, can streamline your development process and ultimately accelerate the commercialization of diagnostic assays and kits. Cytiva can help you speed up and scale up without staffing up! With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical knowledge and talent, a broad and deep portfolio, and exceptional service to support biotechs at every stage from discovery to delivery. Visit cytiva.com/diagnostics to learn more. | Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. | Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in 43 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
CyGenica Limited
CyGenica is a pioneering biotech startup redefining the intracellular delivery of genomic medicines through its proprietary platform, GEENIE — an engineered protein nanoneedle capable of delivering payloads directly into the cytoplasm, bypassing endocytosis. GEENIE enables safe, efficient, and targeted delivery of a broad range of therapeutic modalities including siRNA, ASOs, CRISPR-Cas, and gene therapy vectors, addressing one of the most critical bottlenecks in the field of genetic medicine. Our mission is to empower next-generation therapies with precision delivery tools that overcome biological barriers, reduce off-target effects, and improve therapeutic outcomes — especially in tissues traditionally considered hard to reach such as the brain and eye. CyGenica has secured strategic collaborations with two top-tier global pharma/biotech partners. In one collaboration, we demonstrated that GEENIE enabled a clinically validated RNAi candidate to achieve equivalent gene knockdown efficacy at 100-fold lower doses — a breakthrough with substantial implications for safety, dosing, and cost. Our initial in vivo proof-of-concept (POC) studies demonstrated tissue-specific targeting using GEENIE conjugated to a cytotoxic payload (Maytansine) in glioblastoma models, as well as HER2-gastric cancer tumor xenografts. While these programs validated the platform’s targeting and delivery capabilities, we have strategically pivoted toward higher-value opportunities in CNS and ocular indications, where GEENIE’s unique delivery mechanism offers clear differentiation and unmet need. CyGenica holds four granted patents (2 in the U.S., 1 in Europe, and 1 in Japan), protecting the core GEENIE technology. As we scale our partnerships and pipeline, we are actively seeking collaborators across therapeutic areas to co-develop or license delivery-enabled programs powered by GEENIE.
CustomSurg AG
CustomSurg is a Harvard/ETH Zurich deep-tech venture revolutionizing orthopedic trauma surgery. They have developed Orthoplanner, an FDA-cleared service-designed solution that empowers surgeons to tackle complex trauma surgeries with efficiency. Through accurate 3D fracture surgery planning, it reduces operating time, and enhances patient outcomes, all through an intuitive, cloud-based platform. The company was co-founded by a trauma surgeon, a biomedical engineer, and a serial entrepreneur.
CurveBeam AI
CurveBeam AI’s orthopedic CT systems scan the patient in a functional position for improved deformity evaluation and treatment planning. The HiRise offers custom protocols compatible with vendor joint replacement planning systems. Compared to conventional full body CT imaging, the CurveBeam AI HiRise is less expensive to operate and maintain. Its infrastructure requirements make it practical for the outpatient setting. Scans are billed via standard CPT codes for CT imaging. | CurveBeam AI’s weight bearing CT systems scan the patient while they stand, making it possible to assess functional alignment in three dimensions. The HiRise, CurveBeam AI’s third-generation weight bearing CT system, is a multifunctional solution that can scan the entire lower extremities, including the hip and pelvis. The HiRise offers the largest patient platform in its class and an unprecedented 40 cm diameter field of view. The HiRise gantry tilts 90 degrees for ergonomic upper extremity imaging, as well as supine imaging of the knees and feet. Compared to conventional full body CT imaging, the CurveBeam AI HiRise is less expensive to maintain and operate. Its compact size and infrastructure requirements make it practical for the outpatient setting, including orthopedic clinics. Scans are billed via CPT codes 73700 – CT Lower Extremity and 73200 – CT Upper Extremity.
Curiosis
Curiosis Inc. is dedicated to developing, producing, and supplying innovative systems for cell-based analysis and lab automation. Our advanced solutions are designed to enhance the efficiency, precision, and scalability of cell-based research, helping scientists and medical professionals achieve better outcomes. We strive to establish ourselves as a leader in the bioindustry, focusing on delivering products that meet the evolving needs of both scientific and medical communities. By integrating cutting-edge technologies and fostering continuous innovation, we aim to make significant contributions to the advancement of biomedical research and the improvement of global healthcare outcomes.
Curia
Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of global sites and employees partnering with customers to make treatments broadly accessible to patients. Our biologics offering spans discovery to clinic and fill-finish services across monoclonal antibodies, recombinant proteins and mRNA therapeutics. Our scientific and process experts, and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com/biologics | Curia is a global Contract Development and Manufacturing Organization with over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing to make treatments broadly accessible to patients. Our Biologics offering spans discovery to clinic, including commercial fill-finish services, for monoclonal antibodies, recombinant proteins, mRNA therapeutics, and many large molecule products. Curia’s expertise and agility deliver a best-in-class experience across drug substance and drug product development and manufacturing. From curiosity to cure, we are your trusted ally to accelerate life-changing therapeutics. To learn more visit us at https://curiaglobal.com/biologics/
Cure First
Cure First is a 501 (c)(3) nonprofit organization dedicated to advancing functional precision oncology to improve outcomes for patients with cancer. By working at the intersection of science, clinical care, and patient advocacy, Cure First collaborates with physicians, researchers, biotech partners, and philanthropists to accelerate more effective and personalized treatment strategies. At the core of our approach is the concept of N=1 medicine, where each patient’s tumor is studied as a unique biological system. Through integrated molecular, functional testings, we evaluate how individual cancers respond to therapies rather than relying solely on genomic predictions. Cure First supports a CLIA-certified laboratory offering the PARIS® test (Personalized, Automated, Robotics, Informatics, Sequenced), a high-throughput organoid drug-sensitivity platform that evaluates patient-derived tumor cells against a broad panel of oncology drugs. Results are delivered as a clinical report ranking therapies by predicted effectiveness, helping oncologists select treatments tailored to each patient’s tumor biology. By integrating functional testing with clinical interpretation and multidisciplinary expertise, Cure First aims to expand the reach of precision oncology, accelerate therapeutic discovery, and ultimately transform cancer care from trial-and-error treatment toward evidence-guided individualized therapy.
CTCELLS
CTCELLS is an innovative cancer diagnostics and drug development company founded on the belief that effective cancer care requires solutions tailored to each individual. Powered by Circulating Tumor Cell (CTC) liquid biopsy, CTCELLS enables automated isolation of diverse CTC subtypes to better capture the full biological heterogeneity of cancer. To translate these insights into actionable research and clinical value, CTCELLS integrates its proprietary Continuous Centrifugal Microfluidics (CCM) technology for robust, automated CTC processing, lossless cell staining enabled by hydrogel-based HypICC to preserve cellular information for downstream analysis, and single-cell picking to support precise molecular profiling and functional characterization. By connecting cancer-specific cellular characteristics with the most suitable therapies, CTCELLS is committed to improving patient outcomes and accelerating the development of next-generation treatments, bringing new hope to patients facing difficult-to-treat cancers. | CTCELLS is an innovative biotechnology company striving for a total solution for cancer. With platform technologies in both therapeutics and diagnostics, the RACE platform is designed to deliver safer and more effective immunotherapies by optimizing the selection and administration of treatment based on a patient’s unique immunological profile. The TRACE Platform, on the other hand, is a cutting-edge liquid biopsy system that captures all types of Circulating Tumor Cells (CTCs). This allows for more precise diagnostics and treatment planning, targeting a range of cancer types. CTCELLS is committed to improving patient outcomes by integrating the latest in scientific research and technology into their products.
CS Medical LLC
CS Medical is a leader in developing automated medical devices that clean and high-level disinfect ultrasound probes. Our focus is on delivering scientific-backed solutions that help healthcare professionals reduce patient risk and HAIs. | CS Medical is a leader in medical devices that clean and high-level disinfect transesophageal, transvaginal, transrectal, and surface ultrasound probes. We focus on science-backed solutions that minimize patient risks while providing quality device care and storage by minimizing healthcare operational costs, improving service readiness, and increasing regulatory compliance. Our solutions include point-of-care cleaning, the automation of cleaning and disinfection, drying, storage, and transportation. TEEClean® Automated TEE Probe Cleaner Disinfector and Ethos® Automated Ultrasound Probe Cleaner Disinfector incorporate an FDA-validated cleaning method and remove the labor and time-intensive manual portion of this process. The simple automation of cleaning additionally eliminates the potential risks associated with automated disinfectors that require a clean probe before high-level disinfection in their devices. CS Medical is setting the standard for Complete Probe Reprocessing®.